Stepped care for youths at clinical high risk for psychosis: a real-world study

Alexander Broekhuijse, Psy.D. [1], Abhishek Saxena Ph.D. [1], Barbara Walsh, Ph.D. [1], Catalina Mourgues-Codern, Ph.D. [1], Hesham Mukhtar, MBBS [1], Samantha Howard [1], Scott W. Woods, M.D. [1], Albert R. Powers III, M.D., Ph.D. [1], Emily A. Farina, Ph.D.[1]

1. Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT, USA

Correspondence should be addressed to:

Alex Broekhuijse

The Connecticut Mental Health Center, PRIME Clinic

34 Park Street, New Haven, CT 06519

alex.broekhuijse@yale.edu

(203) 654-7852

Abstract

Objective: Despite recommendations that youths at clinical high risk (CHR) for psychosis receive stepped treatment, few programs have published details of their clinical models or client outcomes. This study describes the implementation and preliminary effectiveness of a risk calculator-informed stepped care model used at the Yale PRIME Clinic, a specialized outpatient clinic for youths at CHR.

Methods: Seventy-one individuals at CHR-P enrolled in Yale's PRIME Clinic during the first phase of the Substance Abuse and Mental Health Services Administration stepped care for CHR-P grant funding period. Participants completed clinical assessments at six timepoints over two years of care. Linear mixed-effect models were fit to examine changes in clinical symptoms over time, and sensitivity analyses evaluated differences in clinical trajectories between completers and non-completers.

Results: Individuals engaged in treatment demonstrated significant and sustained improvements in positive, negative, general, disorganized, and depressive symptoms. Improvements in positive symptoms emerged early and continued to improve across most subsequent timepoints. Pattern mixture analyses suggested that clinical trajectories did not significantly differ between completers and non-completers, though non-completers possessed more heterogenous trajectories.

Conclusions: A stepped care model guided by individualized risk calculator scores is feasible, can be delivered in specialized outpatient settings, and is associated with broad symptom improvement for youths at CHR-P. Further controlled studies with blinded raters

are needed to further support the effectiveness of stepped care models and isolate the active components of treatment.

Highlights:

- Participants at clinical high risk for psychosis enrolled in a risk calculator based stepped care treatment displayed significant reductions in mood and attenuated psychotic symptoms
- The results suggest preliminary evidence for the implementation of a risk calculator based stepped care model.

Introduction

Psychotic disorders are disabling conditions associated with adverse individual, family, and socioeconomic impacts (1,2). Well-validated instruments to detect clinical high risk for psychosis (CHR) syndromes enable earlier identification of individuals at risk for psychosis (3–5), potentially shortening the duration of untreated psychosis or preventing onset altogether (6). Several interventions show promise, including psychosocial interventions (7), cognitive behavioral therapy (CBT) (8), psychoeducation (9), and pharmacotherapy (10,11).

A staged approach to treatment has been recommended by experts (12–14). Stepped care is a sequential clinical approach starting with lower intensity care to increasingly more targeted and specialized treatment, with the goal of optimizing outcomes while minimizing treatment burden. (13). This may be especially beneficial for CHR youths, as starting with the lowest effective level of care may avoid deleterious effects of antipsychotic medication (15). The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) funded 21 sites nationwide in 2018 to design, implement, and evaluate stepped care models for CHR-P, with additional funding in 2022 (16–20).

With this funding, the Yale PRIME Psychosis Risk Clinic developed and implemented a stepped care model guided by a validated psychosis risk calculator tool – the North American Prodrome Longitudinal Study (NAPLS) Risk Calculator (21). This tool quantifies an individuals' likelihood of developing a psychotic disorder within two years, allowing clinicians to tailor treatment intensity to the person's current level of risk. Utilizing objective measurement of symptoms and functioning to personalize care has documented effectiveness for early psychosis and first episode treatment, suggesting it may be equally beneficial for

individuals at CHR (22). Further, stepped care's flexible treatment approach can target common non-psychotic outcomes for CHR youths (23).

Here, we describe a risk-calculator-informed stepped care model for CHR and evaluate its feasibility and effectiveness across two years of treatment. Additionally, we examine factors associated with treatment discontinuation, alongside differences in clinical trajectory and variability between those who completed a full two years of treatment and those who did not. We hypothesized that: (1) participants would display a significant decrease in attenuated psychotic symptoms and depressive symptoms during treatment; (2) participants who disengaged from care would display similar average symptom trajectories to those who remained in care; and (3) despite similar means, participants who discontinued early would have significantly more variable trajectories than those who remained in care, mirroring findings in large scale naturalistic psychotherapy research (24).

Methods

Participants

Between 2018 and 2022, 71 treatment-seeking individuals across Connecticut enrolled in the PRIME Clinic within the Yale School of Medicine in New Haven, Connecticut. Inclusion criteria were (1) ages 12-25 years, (2) IQ$\geq$70, (3) fluency in English, (4) ability to provide informed consent, and (5) met criteria for a CHR-P syndrome based on the Structured Interview for Psychosis Risk Syndromes (SIPS)(4). Participants were largely referred from the local community through the clinic's direct links with schools, mental health and primary care providers, and social services, though participants could also self-refer. This study was approved by the Yale University Institutional Review Board (IRB Approval#: 2000024266).

The PRIME Stepped Care Model

The stepped care model was comprised of three steps (**Figure 1**), providing evidenced-based treatments based on risk and symptom burden, reserving antipsychotic medication for those with the highest symptom burden and conversion risk. "Adjunctive care" addressed other needs across all steps, including pharmacotherapy for common comorbid, brief family interventions, and collaboration with school-based providers; utilization was not logged. Implementation details are in the Online Supplement.

Each client completed the NAPLS risk calculator assessment after being identified at CHR with the SIPS, following Step One, and every six months of care. This risk calculator guided which step of treatment each client received. Movement through steps was flexible, and participants moved forward or backward as needed. Cutoffs for step movement were conservative estimates drawn from existing research suggesting a 30% two year transition rate (25,26). While clinicians used the risk calculator to identify the appropriate step of care for each client, client preferences were prioritized when coordinating treatment decisions. For example, if a client's risk calculator score did not indicate the need for antipsychotic medication, but the client's APS were distressing or an impediment to functioning, the psychiatry team would consider the risks and benefits of anti-psychotic medication with the patient and family. Non-psychosis factors were not considered in stepping decisions.

Step One: Brief supportive psychoeducation (BSP)

All participants began treatment with BSP, a flexible psychoeducational intervention for CHR-P originally utilized in the NAPLS studies. Content included education about CHR-P symptoms, the vulnerability-stress model, the role of the clinician and family, problem-solving, coping strategies, and identification of personalized risk and protective factors. BSP

was delivered over three sessions within two months of baseline. Participants who achieved

CHR-P partial remission (one consecutive month with all positive symptoms scored at a two

or less on the SIPS (27)) following BSP were then offered remission care, consisting of in-

person BSP booster sessions (minimum every six months), telephone monitoring (minimum

every two months), and adjunctive care as needed.

Step Two: Personalized CBT for Early Psychosis (P-CBT-EP)

Individuals who reached Step Two were offered P-CBT-EP, a flexible manualized cognitive-

behavioral intervention tailored to early psychosis symptoms. P-CBT-EP was intended to be

delivered in 15 sessions over approximately six months. Content included the relation

between thinking, feeling, and behavior, cognitive distortions, automatic negative thoughts,

probability overestimation, jumping to conclusions, and exposure. While P-CBT-EP attends

to positive symptoms, its content is derived from core cognitive-behavioral theory and could

be adapted for participants meeting CHR criteria for familial risk and functional decline

alone. Participants continued to work with their assigned psychotherapist from Step One

across all steps. While other psychotherapies have been validated for CHR youths, these

therapies were not widely available or tested in 2017.

Participants who did not achieve partial remission after BSP received Step Two. Those with a

risk score <33% received Step Two alone; those with a risk score ≥ 33% after Step One BSP

and/significantly distressing CHR-P symptoms were offered both Step Two and Step Three.

After completion of Step Two care, participants achieving partial remission proceeded to

remission and adjunctive care as for Step One. Participants who were not in remission but

whose two-year risk of psychosis is < 15% proceeded to P-CBT-EP booster sessions and

adjunctive care. Lastly, participants who were not in remission, but whose two-year risk of psychosis was ≥ than 15% proceeded to Step Three.

Step Three: Consideration of psychotropic medication

Participants who reached Step Three were offered antipsychotic and/or antidepressant medication if their CHR-P symptoms were distressing and impairing as assessed by the SIPS. Choice of medication was based on client preference related to adverse event profile, and dosing was based on the minimum dose that sustains remission with minimal emergent adverse effects. Medication decision making and evaluation were performed by the PRIME Clinic's medical director and a team of psychiatry residents and fellows. Remission and adverse effects were monitored through monthly appointments with psychiatrists and regularly scheduled evaluations.

Assessments

Clinical status and functioning were assessed at baseline, and months 2, 6, 12, 18, and 24. Participants also received as-needed assessment if conversion to psychosis was suspected. Assessments administered included a sociodemographic questionnaire, all instruments included in the risk calculator, the Columbia Suicide Severity Scale, the SIPS, and SAMHSA's National Outcome Measures (NOMs), including the Patient Health Questionnaire, Nine (PHQ-9) (28).

The NAPLS psychosis risk calculator (21) is an individualized prognostic tool derived from the NAPLS-2 cohort which utilizes six assessments to estimate one- and two-year transition to psychosis risk for individuals that meet CHR criteria. Details on calculator assessments and administration protocol can be found in the Online Supplement.

The SIPS is a structured clinical interview composed of four scales that measure positive symptoms (range 0-30) and negative symptoms (range 0-36), disorganized communication (range 0-24), and general psychopathological concerns (range 0-24). Each positive symptom item is scored on a scale of 0 (Absent) to 5 (Severe but Not Psychotic), with a 6 indicating the presence of frank psychosis. A comprehensive review of studies utilizing the SIPS suggests an average total positive symptom score of scores of 9.9, while nationwide longitudinal research suggests averages of 11.92 (negative), 5.15 (disorganized), and 9.19 (general) for individuals at CHR (29,30). CHR status was identified by the criteria of prodromal symptoms (COPS) as detailed in the SIPS.

All assessments were completed by each participant's assigned psychotherapists at each timepoint. Clinicians were trained in the administration of the SIPS through a two-day certification process, and all individual components of the NAPLS risk calculator.

Statistical analysis

Statistical analyses were conducted in R version 4.5.1. Descriptive analyses were run to examine participant sociodemographic and clinical characteristics. For Scale of Psychosis Risk Symptoms (SOPS) total and PHQ-9 scores, linear mixed effects models were fit in accordance with the intent-to-treat principle, adjusted for age and sex, with time as a categorical fixed effect and a random intercept for each client (REML; Satterthwaite degrees of freedom). Intraclass-correlation and fixed/conditional R^2 values were calculated to evaluate model fit. Pairwise contrasts (Tukey) were performed to compare individual timepoints. Linear mixed-effects models enabled the use of all available measurements regardless of

missing observations under a Missing-At-Random (MAR) assumption (31). All data for included model covariates was complete.

Pattern mixture analyses were run as Missing-Not-At-Random (MNAR) sensitivity analyses and to examine whether clinical trajectories differed by retention and disengagement. For pattern mixture analyses, participants were classified by last observed visit (completers, disengagement at 6, 12, 18, and 24 months). Within each cutoff, we fit linear mixed-effects models with timepoint, pattern (reached, did not reach), and their interaction as fixed effects, with participant ID as a random effect.

To evaluate whether early treatment discontinuation prior to two years was associated with greater heterogeneity in clinical outcomes, we compared the homogeneity of variance across completers and non-completers at 12, 18, and 24 months using the Brown-Forsythe test (median centred Levene).

Results

Participants

Table 1 includes sociodemographic and clinical characteristics at baseline. Of the 71 individuals enrolled, 58% of participants were male. The average participant age was 15.6 years old (SD=2.69), and participants were 53.5% White, 35.2% Black, 4.2% Asian, 2.8% Indigenous American/Alaskan, and 4.2% "Other" unlisted race. All participants were proficient in English.

Eight participants entered the study with already prescribed anti-psychotic medication, while 20 entered with already prescribed anti-depressant medication. During treatment, 20 additional participants were prescribed antipsychotic and/or antidepressant medication.

At baseline, participants presented with above-average positive (M=13.9, SD=3.03), negative (M=13.0, SD=4.50), and general (M=12.9, SD=3.35) symptoms, average disorganized (M=5.36, SD=2.30) symptoms compared to published norms detailed above, as well as moderate depressive symptoms (PHQ-9; M=13.81, SD=5.99). Analysis using the NAPLS risk calculator estimated a 20.03% (SD=11.63) one-year and a 25.66% (SD=14.35) two-year average conversion risk for participants.

Of the 71 total enrolled participants, 25 (35.2%) completed the full two-year protocol, 12 (16.9%) were discharged due to full symptom remission as defined by SIPS criteria, 10 (14.1%) were discharged due to repeated no-show appointments, 5 (7%) were discharged due to conversion to psychosis, and 19 (26.8%) voluntarily withdrew from treatment. Participants who left treatment, including those discharged due to symptom remission,- were not reevaluated. Of those who completed two years of treatment, 45% achieved full remission by the 24 month assessment. Attrition occurred gradually across timepoints, with 71 participants at baseline, 54 (76%) participants at two months, 43 (60%) participants at six months, 40 participants at 12 months (56%), 36 participants at 18 months (51%), and 26 participants at 24 months (37%). Overall, 71 participants participated in Step 1, 54 participants participated in Step 2, and 20 participants participated in Step 3. No participants moved backwards between steps.

H1: Change in participant clinical outcomes

To evaluate symptom change, linear mixed-effects models were run on 267 observations across 71 participants. An intraclass correlation coefficient was calculated to identify the total variance attributable to between-participant differences. Intraclass correlations suggested moderate clustering within participants and moderate within-person similarity among repeated measures (Positive symptoms=0.46, Negative symptoms=0.54, General symptoms=0.44, Disorganization symptoms=0.42, PHQ-9=0.48).

Symptom trajectories are visualized in **Figure 2.** Timepoint effects were significant for all symptom domains, including positive ($F(5, 204)=78.40$, $p<0.001$), negative ($F(5, 171)=26.40$, $p<0.001$), disorganized ($F(5, 174)=7.55$, $p<0.001$), general ($F(5, 177)=29.89$, $p<0.001$), and depressive symptom severity ($F(5, 196)=27.02$, $p<0.001$).

Estimated marginal means (EMMs) declined from baseline to 24 months for all outcomes, with significant baseline contrasts at multiple timepoints after multiplicity control. At 12 months, participants showed significant reductions in positive ($\Delta=7.25$, $p<0.001$), negative ($\Delta=4.86$, $p<0.001$), general ($\Delta=4.55$, $p<0.001$), disorganized ($\Delta=1.45$, $p=.011$), and depressive symptoms ($\Delta=7.29$, $p<0.001$). Positive ($\Delta=3.34$, $p<0.001$), negative ($\Delta=2.97$, $p=0.018$), and general ($\Delta=2.12$, $p=0.05$) symptoms continued improving through 24, while disorganized and depressive symptoms stabilized. Change in positive, and general symptoms reached significance at 6 months; whereas disorganized symptoms by 12 months; and depressive symptoms by 2 months.

Fixed effects accounted for 48% of variance in positive symptoms (marginal $R^2=0.48$), increasing to 72% when including random effects (conditional $R^2=0.72$). Other symptom domains possessed greater between-person heterogeneity (N=0.25→0.65; G=0.31→0.61;

D=0.12→0.49; PHQ-9=0.28→0.62). Model summaries and EEMs with 95% CIs are reported in Table 2 (Holm vs. Baseline); timepoint-wise contrasts (Tukey all-by-all) are in the online supplement.

H2: Difference in trajectory by disengagement timepoint

Pattern-mixture sensitivity analyses were used to examine whether clinical change varied by disengagement status. Across symptom domains, interaction effects (timepoint x pattern) were mostly non-significant, providing no evidence that clinical symptoms separated completers from non-completers. Two exceptions were noted for negative symptoms at the 6-month ($F(2, 49)=6.46$, $p=0.014$) and 12-month ($F(2, 82) =5.73$, $p<0.01$) assessments, where non-completers showed lower negative symptoms. Otherwise, completers and non-completers demonstrated statistically similar improvements across treatment. Group-level trajectories between completers and non-completers and individual and mean participant change scores are visualized in the online supplement.

H3: Variability in symptom trajectory by retention status

Brown-Forsythe tests indicated heteroscedasticity for positive symptoms ($F=(2,10)$ 9.48, $p<0.001$) and PHQ-9 scores ($F (2,11)=4.94$, $p<0.001$), and homoscedasticity for negative symptoms, general symptoms, and disorganized symptoms. For positive symptoms and PHQ-9 scores, non-completers had significantly more variability in their clinical scores than completers.

Discussion

In this outpatient sample of youths at CHR-P, a risk calculator informed stepped care model was feasible and associated with sizable improvements in psychotic and depressive

symptoms over two years. Main findings were that 1) participants demonstrated significant and sustained improvements in positive, negative, general, disorganized, and depressive symptoms across two years of stepped care treatment; 2) symptom trajectories were comparable between treatment completers and non-completers, suggesting early disengagement was not primarily driven by clinical worsening, and 3) symptom variability was greater among non-completers, indicating more heterogenous patterns of change in those who discontinued care early. Further, 56% of participants remained enrolled in care for at least one year of treatment, and the full completion rate was comparable to rates in general outpatient mental health care in the United States and psychosocial treatment trials amongst CHR youths (32–34).

Our findings demonstrate that a sequential, risk-guided model can be successfully delivered in a specialized outpatient environment while being associated with meaningful clinical improvement. Consistent reductions across symptom domains, particularly in positive and depressive symptoms, indicate that our model was associated with transdiagnostic symptom relief. These results align with prior research showing significant within-subject improvement among youths at CHR-P engaged in cognitive-behavioral or psychoeducational interventions (35). While causative associations cannot be made as this is an uncontrolled pre-post study, these findings are promising, especially given the considerable transdiagnostic comorbidity present amongst individuals at CHR. By 12 months, 25% of participants had achieved full remission, rising to 36.6% at 18 months and 50% by 24 months, comparable to documented remission rates in observational studies (36). The observed conversion rate (9.58%) was significantly below estimates provided by the NAPLS Risk Calculator at baseline (25%; exact binomial test, $p < .001$). However, the calculator was developed in an observational cohort, and its calibration in treatment seeking samples remain understudied (37); the

discrepancy may reflect treatment effects, population differences, or both. Additionally, clinician feedback indicate it was easily usable, and assessments offered valuable treatment insights.

Nonsignificant differences in clinical trajectories between completers and non-completers suggest that early treatment disengagemetn may not be primarily driven by symptom exacerbation or treatment ineffectiveness. Clinician observations point to non-clinical drivers of disengagement, as many participants chose to discharge early to engage in social, academic, and occupational activities, suggesting improvements in functioning over time. Fewer negative symptoms amongst non-completers may be associated with greater activity.

This study adds to the limited evidence based describing the implementation and outcomes of a stepped care framework for CHR. Prior work indicated that risk-informed or staged approaches may reduce overtreatment and optimize resource allocation by reserving higher-intensity interventions for individuals with the greatest need (16,19). Our results add to the growing literature on stepped care for CHR, replicating benefits for positive symptoms and identifying novel improvements in negative, general, disorganization, and depressive symptoms (16,18–20,38).

Interpretation should consider several limitations. First, as an uncontrolled pre-post study, improvements could reflect regression to the mean, naturalistic improvement, or concurrent treatment effects. Secondly, data on intervention fidelity, the relative contributions of individual steps, patient satisfaction, or concurrent services was not collected. Third, SIPS evaluations were conducted by participants' psychotherapists, raising the possibility of allegiance or expectancy effects. Fourth, missing data limited potential analyses, including

analyses of patient functioning. Fifth, we implemented this approach in a speciality clinic and the feasibility of this model in settings with limited training in psychosis risk remains unclear. Seventh, eight participants entered the study with previous antipsychotic and antidepressant exposure, which may have influenced their response to treatment. Eighth, heterogeneous reasons for disengagement may have influenced sensitivity analyses.

Conclusion

A risk calculator-informed, stepped care model for youths at CHR is feasible to implement in specialized settings and associated with broad sustained improvement across symptom domains. Integrating individualized risk prediction with staged treatment bridges the gap between empirically informed precision risk assessment and clinical practice. Given that disengagement appears driven by non-clinical factors, tailoring care to youths interest and scheduling demands may increase retention. Further research is needed to identify relative contributions of individual steps, compare to control conditions, and minimize the impact of concurrent treatments. -

Acknowledgements: This work was funded by SAMHSA Grant Number: 6H79SM081190-01M001. Additionally, this work was funded in part by the State of Connecticut, Department of Mental Health and Addiction Services, but this publication does not express the views of the Department of Mental Health and Addiction Services or the State of Connecticut. The views and opinions expressed are those of the authors.

References

1.   Eaton WW: The burden of mental disorders. Epidemiol Rev 30: 1-14, 2008.

2.   Arias D, Saxena S, Verguet S: Quantifying the global burden of mental disorders and their economic value. EClinicalMedicine 54: 101675, 2022.

3. Woods SW, Addington J, Cadenhead KS, et al.: Validity of the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome Longitudinal Study. Schizophrenia Bulletin 35: 894–908, 2009.

4. Miller TJ, McGlashan TH, Rosen JL: Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin 29: 703–715, 2003.

5. Woods SW, Lympus C, McGlashan TH, et al.: The Mini-SIPS: development of a brief clinical structured interview guide to diagnosing DSM-5 Attenuated Psychosis Syndrome and training outcomes. BMC Psychiatry 22: 784, 2022.

6. Fusar-Poli P, McGorry PD, Kane JM: Improving outcomes of first-episode psychosis: an overview. World Psychiatry 16: 251-265, 2017.

7. Fusar-Poli P: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence. Front Psychiatry 10: 764, 2019.

8. Zheng Y, Xu T, Zhu Y, et al.: Cognitive Behavioral Therapy for Prodromal Stage of Psychosis—Outcomes for Transition, Functioning, Distress, and Quality of Life: A Systematic Review and Meta-analysis. Schizophrenia Bulletin 48: 8–19, 2022.

9. Herrera SN, Sarac C, Phili A, et al.: Psychoeducation for individuals at clinical high risk for psychosis: A scoping review. Schizophrenia Research 252: 148–158, 2023.

10. Woods SW, Addington J, Bearden CE, et al.: Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research 148: 99–104, 2013.

11. Mukhtar H, Zhou D, Farina EA, et al.: Prediction of antipsychotic medication inception in antipsychotic-naive youth at clinical high risk for psychosis. Psychol Med 55: e241, 2025.

12. Breitborde NJK: The Ohio State University Early Psychosis Intervention Center (EPICENTER) stepped care programme for individuals at clinical high risk for psychosis: study protocol for an observational study. BMJ Open 10: 034031, 2020.

13. McGorry PD, Mei C, Amminger GP, et al.: A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial. JAMA Psychiatry 80: 875, 2023.

14. Nelson B: Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Early Interv Psychiatry 12: 292-306, 2018.

15. Di Lisi A, Pupo S, Menchetti M, et al.: Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice. J Clin Psychopharmacol 44: 502–508, 2024.

16. Cosgrove JA, Crocker LD, Breitborde NJK, et al.: Stepped Care Interventions for Psychosis Risk: Findings From Clinical High Risk for Psychosis Grantee Programs. PS appi.ps.20240505, 2025.

17. Addington J, Liu L, Braun A, et al.: Treatment Choices for Youth at Clinical High-Risk of Psychosis: Methods of an Open Trial. Early Intervention Psych 19: e70068, 2025.

18. Shapiro DI, Grattan RE, Laquidara JR, et al.: Feasibility of a Stepped-Care Intervention for Those at Clinical High Risk for Psychosis in the United States. Early Intervention Psych 20: e70120, 2026.

19. Hamilton SA: Symptomatic and Functional Outcomes Among Individuals at High Risk for Psychosis Participating in Stepped Care. Psychiatr Serv appips20230188, 2023.

20. Moe AM, Cowan HR, Manges M, et al.: The influence of complex psychiatric comorbidities on treatment for clinical high-risk for psychosis: A preliminary study. Early Intervention Psych 18: 888–893, 2024.

21. Cannon TD, Yu C, Addington J: An individualized risk calculator for research in prodromal psychosis. American Journal of Psychiatry 173: 980-988, 2016.

22. Kane JM, Robinson DG, Schooler NR, et al.: Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. AJP 173: 362–372, 2016.

23. Solmi M, Soardo L, Kaur S: Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment. Molecular Psychiatry 28: 2291-2300, 2023.

24. Zieve GG, Persons JB, Yu LAD: The Relationship Between Dropout and Outcome in Naturalistic Cognitive Behavior Therapy. Behavior Therapy 50: 189–199, 2019.

25. Salazar De Pablo G, Radua J, Pereira J, et al.: Probability of Transition to Psychosis in Individuals at Clinical High Risk: An Updated Meta-analysis. JAMA Psychiatry 78: 970, 2021.

26. Carrión RE, Cornblatt BA, Burton CZ, et al.: Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project. AJP 173: 989–996, 2016.

27. Woods SW, Walsh BC, Addington J, et al.: Current status specifiers for patients at clinical high risk for psychosis. Schizophrenia Research 158: 69–75, 2014.

28. Kroenke K, Spitzer RL, Williams JBW: The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16: 606–613, 2001.

29. Addington J, Liu L, Buchy L, et al.: North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. Journal of Nervous & Mental Disease 203: 328–335, 2015.

30. Woods SW, Walsh BC, Powers III AR, et al.: Reliability, Validity, Epidemiology, and Cultural Variation of the Structured Interview for Psychosis-Risk Syndromes (SIPS) and

the Scale of Psychosis-Risk Symptoms (SOPS); in Handbook of Attenuated Psychosis Syndrome Across Cultures. Edited by Li H, Shapiro DI, Seidman LJ, et al. Springer Nature Switzerland AG, 2019.

31. Schafer JL, Yucel RM: Computational strategies for multivariate linear mixed-effects models with missing values. Journal of Computational and Graphical Statistics 11: 437–457, 2002.

32. Olfson M, Mojtabai R, Sampson NA: Dropout from outpatient mental health care in the United States. Psychiatric Services 60: 898–907, 2009.

33. Leopold K, Bauer M, Bechdolf A, et al.: Efficacy of cognitive-behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study. Bipolar Disorders 22: 517–529, 2020.

34. Parker SK, Mulligan LD, Milner P, et al.: Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study. Front Psychol 10: 2741, 2020.

35. Mei C: Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis. Clin Psychol Rev 86: 102005, 2021.

36. Seitz-Holland J, Jacobs GR, Reinen J, et al.: Incidence, Prevalence, and Stability of Remission in Individuals With Clinical High Risk for Psychosis. JAMA Netw Open 8: e2525644, 2025.

37. Worthington MA, Miklowitz DJ, O'Brien M, et al.: Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator. Early Intervention Psych 15: 96–103, 2021.

38. West ML, Parrish EM, Friedman-Yakoobian M: Treatment outcomes for young people at clinical high risk for psychosis: Data from a specialized clinic. Early Intervention Psych 16: 500–508, 2022.

39. Keefe R: The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research 68: 283–297, 2004.

40. Benedict RHB, Schretlen D, Groninger L, et al.: Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. The Clinical Neuropsychologist 12: 43–55, 1998.

Figure 1. The stepped care model for CHR-P employed at the PRIME clinic.

Figure 2. Adjusted SIPS scores by timepoint (baseline to 24 months). Linear mixed effects models adjusted for age and sex. Points are estimated marginal means, and shading indicates 95% confidence intervals. Positive (P), negative, (N), general (G), and disorganized (D) symptoms are each represented by an individual line. A ○ indicates no significant change, a ● indicates significant change compared to baseline, and a ♦ indicates both a significant change compared to baseline and compared to the previous measurement point.

Table 1. *Demographic and Baseline Clinical Characteristics*

Baseline Characteristic	Overall	Male mean	Female mean
Age (years)	15.61 ± 2.69	15.29	16.07
Sex			
Male	41 (57.7%)		
Female	30 (42.3%)		
Race			
White	38 (53.5%)		
Black	25 (35.2%)		
Asian	3 (4.2%)		
Indigenous American	2 (2.8%)		
Other	3 (4.2%)		
Clinical Characteristics			
Positive symptoms (baseline)	13.89 ± 3.03	14.29	13.33
General symptoms (baseline)	12.87 ± 3.35	13.46	12.03
Negative symptoms (baseline)	12.99 ± 4.50	12.98	13.00
Disorganized symptoms (baseline)	5.36 ± 2.30	5.88	4.62
Patient Health Questionnaire, 9 (baseline)	13.81 ± 5.99	14.56	12.81

Overall column shows mean ± SD; Male/Female columns show means.

Table 2. Changes in estimated SIPS and PHQ-9 scores from baseline to each subsequent measurement point

Outcome	Timepoint	n	EMM ± SE	95% CI (EMM)	Δ vs baseline†	95% CI (Δ)	t(df)	p (Holm)	F (timepoint omnibus)	p (omnibus)
P	baseline	71	13.75 ± 0.47	[12.82, 14.68]					F(5, 204.41) = 78.40	<.001
	2mo	54	12.48 ± 0.52	[11.46, 13.51]	-1.27	[-2.65, 0.11]	-2.39(203.64)	0.018		
	6mo	43	10.03 ± 0.56	[8.92, 11.13]	-3.72	[-5.21, -2.24]	-6.51(206.25)	<.001		
	12mo	40	6.50 ± 0.58	[5.36, 7.64]	-7.25	[-8.78, -5.72]	-12.33(207.83)	<.001		
	18mo	36	5.38 ± 0.60	[4.19, 6.57]	-8.37	[-9.96, -6.78]	-13.69(208.62)	<.001		
	24mo	26	3.16 ± 0.69	[1.81, 4.51]	-10.59	[-12.39, -8.79]	-15.32(208.54)	<.001		
G	baseline	70	12.76 ± 0.46	[11.86, 13.66]					F(5, 177.76) = 29.89	<.001
	2mo	45	11.64 ± 0.54	[10.58, 12.70]	-1.12	[-2.56, 0.32]	-2.03(177.66)	0.044		
	6mo	34	9.46 ± 0.59	[8.29, 10.63]	-3.30	[-4.89, -1.72]	-5.44(179.86)	<.001		
	12mo	32	8.21 ± 0.61	[7.01, 9.41]	-4.55	[-6.17, -2.93]	-7.31(180.29)	<.001		
	18mo	31	7.24 ± 0.62	[6.03, 8.46]	-5.52	[-7.16, -3.88]	-8.75(180.03)	<.001		
	24mo	23	6.09 ± 0.70	[4.71, 7.46]	-6.67	[-8.52, -4.83]	-9.43(181.19)	<.001		
N	baseline	70	13.27 ± 0.59	[12.10, 14.45]					F(5, 170.59) = 26.40	<.001
	2mo	45	12.35 ± 0.68	[11.00, 13.70]	-0.92	[-2.62, 0.78]	-1.41(171.41)	0.160		
	6mo	34	10.21 ± 0.75	[8.74, 11.69]	-3.06	[-4.93, -1.19]	-4.26(172.91)	<.001		
	12mo	32	8.42 ± 0.76	[6.91, 9.93]	-4.86	[-6.77, -2.94]	-6.59(173.19)	<.001		
	18mo	31	7.53 ± 0.77	[6.01, 9.06]	-5.74	[-7.68, -3.80]	-7.70(172.85)	<.001		
	24mo	23	5.45 ± 0.86	[3.74, 7.15]	-7.83	[-10.01, -5.65]	-9.35(173.48)	<.001		
D	baseline	70	5.43 ± 0.31	[4.82, 6.03]					F(5, 174.44) = 7.55	<.001
	2mo	45	5.84 ± 0.36	[5.13, 6.56]	0.41	[-0.57, 1.40]	1.09(174.11)	0.551		
	6mo	34	5.05 ± 0.40	[4.26, 5.84]	-0.38	[-1.46, 0.70]	-0.92(176.63)	0.551		
	12mo	32	3.98 ± 0.41	[3.17, 4.80]	-1.45	[-2.55, -0.34]	-3.40(177.12)	0.003		
	18mo	31	4.03 ± 0.42	[3.20, 4.85]	-1.40	[-2.52, -0.28]	-3.26(176.87)	0.004		
	24mo	23	3.39 ± 0.47	[2.46, 4.33]	-2.04	[-3.29, -0.78]	-4.22(178.23)	<.001		
PHQ-9	baseline	63	13.42 ± 0.67	[12.09, 14.75]					F(5, 196.23) = 27.02	<.001
	2mo	51	9.67 ± 0.72	[8.25, 11.10]	-3.75	[-5.68, -1.81]	-5.04(196.78)	<.001		
	6mo	45	8.76 ± 0.75	[7.28, 10.25]	-4.65	[-6.67, -2.64]	-6.00(199.02)	<.001		
	12mo	40	6.12 ± 0.79	[4.57, 7.68]	-7.29	[-9.40, -5.19]	-9.01(201.53)	<.001		
	18mo	35	5.96 ± 0.83	[4.33, 7.59]	-7.46	[-9.67, -5.25]	-8.78(202.28)	<.001		
	24mo	25	4.89 ± 0.94	[3.03, 6.75]	-8.53	[-11.02, -6.03]	-8.88(202.14)	<.001		

† Δ vs baseline; Holm-adjusted p-values. R²(marginal/conditional) and ICC by outcome are reported in text.